Stock Market News
ValiRx rockets on 'increased confidence' in lung cancer trials
Clinical stage biotechnology company ValiRx has completed data collection from a recent Phase II trial on its lung cancer treatment and is now taking steps towards completing a clinical study report for submission.
Since ValiRx released the results of its VAL401 trial on 16 January, the firm switched its development focus on commercial areas, consulting an advisory board of UK Key Opinion Leaders, addressing the significance of the results obtained and the positioning of VAL401 in the UK and global market.
ValiRx has continued advanced conversations with a number of prospective partners with the aim of achieving a partnership, to progress the project appropriately towards eventual patient use and has been approved for a second patent in New Zealand for VAL401's use in the treatment of pancreatic adenocarcinoma.
Dr Suzy Dilly, chief executive of ValiRx's joint venture with Tangent Reprofiling, ValiSeek, said, "The external validation from both the advisory board and wider industry, has provided increased confidence that VAL401, the product, has a valued and needed place in the market. These developments are a valuable addition to our licensing package, clarifying the final stages of clinical testing towards commercial use."
As of 0900 BST, ValiRx shares had rocketed 26.67% to 2.85p.
Since ValiRx released the results of its VAL401 trial on 16 January, the firm switched its development focus on commercial areas, consulting an advisory board of UK Key Opinion Leaders, addressing the significance of the results obtained and the positioning of VAL401 in the UK and global market.
ValiRx has continued advanced conversations with a number of prospective partners with the aim of achieving a partnership, to progress the project appropriately towards eventual patient use and has been approved for a second patent in New Zealand for VAL401's use in the treatment of pancreatic adenocarcinoma.
Dr Suzy Dilly, chief executive of ValiRx's joint venture with Tangent Reprofiling, ValiSeek, said, "The external validation from both the advisory board and wider industry, has provided increased confidence that VAL401, the product, has a valued and needed place in the market. These developments are a valuable addition to our licensing package, clarifying the final stages of clinical testing towards commercial use."
As of 0900 BST, ValiRx shares had rocketed 26.67% to 2.85p.
Related share prices |
---|
Valirx (VAL) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price